Introduction {#Sec1}
============

The acute respiratory distress syndrome (ARDS) is a major problem in the intensive care unit (ICU) with a prevalence of 10% and an in-hospital mortality rate of 40% \[[@CR1], [@CR2]\]. ARDS pathophysiology is based on a triad of alveolar-capillary membrane injury, high permeability alveolar oedema, and migration of inflammatory cells \[[@CR3]\]. This triad is not routinely measured in clinical practice. Therefore, arterial hypoxemia and bilateral opacities on chest imaging following various clinical insults are used as clinical surrogates in the American European Consensus Conference (AECC) definition and the newer Berlin definition of ARDS \[[@CR4], [@CR5]\].

Histologically, ARDS is characterized by diffuse alveolar damage (DAD). The correlation between a clinical and histological diagnosis of ARDS is poor \[[@CR6]\]. Only half of clinically diagnosed patients with ARDS have histological signs of DAD at autopsy \[[@CR7]--[@CR10]\]. The number of risk factors for ARDS and consequently the heterogeneous histological substrates found in patients with clinical ARDS have been recognized as a major contributor to the negative randomized controlled trial results among patients with ARDS \[[@CR11]\].

It has been suggested that the addition of biomarkers to the clinical definition of ARDS could reduce ARDS heterogeneity by the identification of subgroups \[[@CR12]--[@CR15]\]. A retrospective latent class analysis of large randomized controlled trials identified two ARDS phenotypes largely based on ARDS biomarkers combined with clinical parameters \[[@CR16], [@CR17]\]. These phenotypes responded differently to the randomly assigned intervention arms. Prospective studies are required to validate these ARDS phenotypes and their response to interventions. The set of ARDS biomarkers to prospectively define these phenotypes remains to be established.

Numerous biomarkers and their pathophysiological role in ARDS have been described \[[@CR12], [@CR18]\]. In an earlier meta-analysis, biomarkers for ARDS development and mortality were examined in univariate analysis \[[@CR19]\]. However, pooling of univariate biomarker data may result in overestimation of the actual effect. For this reason, we conducted a systematic review and included all biomarkers that were multivariately associated with ARDS development or mortality. This study provides a synopsis of ARDS biomarkers that could be used for future research in the identification of ARDS phenotypes.

Methods {#Sec2}
=======

This systematic review was prospectively registered in PROSPERO International Prospective Register of Systematic Reviews (PROSPERO identifier CRD42017078957) and performed according to the Transparent Reporting of Systematic Reviews and Meta-analyses (PRISMA) Statement \[[@CR20]\]. After the search strategy, two reviewers (PZ, PS, and/or WG) separately performed study eligibility criteria, data extraction, and quality assessment. Any discrepancies were resolved by consensus, and if necessary, a third reviewer was consulted.

We searched for studies that included biomarkers that were associated with ARDS development in critically ill patients at risk for ARDS and mortality in the ARDS population in multivariate analyses adjusted for background characteristics. We did not perform a meta-analysis, because the raw data in all studies was either not transformed or log transformed resulting in varying risk ratios and confidence intervals. In addition, the majority of studies used different biomarker concentration cut-offs, resulting in varying concentration increments for risk ratios. Lastly, the number of days until mortality and variables used in multivariate analysis differed between studies. For these reasons, we limited this study to a systematic review, as the multivariate odds ratios were not comparable and pooling would result in non-informative estimates \[[@CR21]\].

Search strategy {#Sec3}
---------------

We performed a systematic search in Embase, MEDLINE, Web of Science, Cochrane CENTRAL, and Google Scholar from inception until 30 July 2018 with assistance from the Erasmus MC librarian. The search was later updated to 6 March 2020. A detailed description of the systematic search string is presented in Additional file [1](#MOESM1){ref-type="media"}. In addition, the reference lists of included studies and recent systematic reviews were screened to identify additional eligible studies.

Study eligibility criteria {#Sec4}
--------------------------

All retrieved studies were screened on the basis of title and abstract. Studies that did not contain adult patients at risk for ARDS or with ARDS and any biomarker for ARDS were excluded. The following eligibility criteria were used: human research, adult population, studies in which biomarkers were presented as odds ratios (OR) or risk ratios in multivariate analysis with ARDS development or mortality as outcome of interest, peer-reviewed literature only, and English language. Studies comparing ARDS with healthy control subjects, case series (\< 10 patients included in the study), and studies presenting gene expression fold change were excluded.

Data extraction {#Sec5}
---------------

A standardized form was used for data extraction from all eligible studies. Two clinical endpoints were evaluated in this study: development of ARDS in the at-risk population (patients that did develop ARDS versus critically ill patients that did not) and mortality in the ARDS population (survivors versus non-survivors). The following data were extracted: study design and setting, study population, sample size, the definition of ARDS used in the study, outcome, risk ratio with 95% confidence interval in multivariate analyses, and the variables used in the analyses. In addition, the role of the biomarker in ARDS pathophysiology as reported by the studies was extracted and divided into the following categories: increased endothelial permeability, alveolar epithelial injury, oxidative injury, inflammation, pro-fibrotic, myocardial strain, coagulation, and others. Subsequently, the relative frequency distribution of biomarker roles in ARDS pathophysiology was depicted in a bar chart.

Quality assessment {#Sec6}
------------------

Methodological quality of the included studies was assessed with the Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in systematic reviews and meta-analyses \[[@CR22]\]. Items regarding patient selection, comparability, and outcome were assessed using a descriptive approach, and a risk-of-bias score, varying between 0 (high risk) and 9 (low risk), was assigned to each study.

Results {#Sec7}
=======

Literature search and study selection {#Sec8}
-------------------------------------

A total of 8125 articles were identified by the initial search and 972 by the updated search (Fig. [1](#Fig1){ref-type="fig"}). After removal of duplicates and reviewing titles and abstracts, we selected 438 articles for full-text review. A total of 86 studies was eligible for data extraction: 35 for ARDS development and 53 for ARDS mortality. Fig. 1PRISMA flow diagram for a systematic search

Study characteristics and quality assessment {#Sec9}
--------------------------------------------

The study characteristics of the 35 studies for ARDS development are presented in Table [1](#Tab1){ref-type="table"}. A total of 10,667 critically ill patients was at risk for ARDS, of whom 2419 (24.6%) patients developed ARDS. The majority of studies used the Berlin definition of ARDS (21/35), followed by the AECC criteria of ARDS (13/35). The included biomarkers were measured in plasma, cerebrospinal fluid, and bronchoalveolar lavage fluid. In all studies, the first sample was taken within 72 h following ICU admission. Table 1Study characteristics for ARDS developmentStudyStudy designStudy populationARDS definitionOutcomeTotal (***n***)ARDS (***n***)AgeGender, male ***n*** (%)Variables in multivariate analysisSample momentAgrawal 2013 \[[@CR23]\]Prospective cohortCritically illAECCALI1671969 ± 168 (42.1%)APACHE II score, sepsisWithin 24 h following admissionAhasic 2012 \[[@CR24]\]Case-controlCritically illAECCARDS53117560.7 ± 17.6102 (58.2%)Age, gender, APACHE III score, BMI, ARDS risk factorWithin 48 h following admissionAisiku 2016 \[[@CR25]\]RCT (TBI trial)Critically ill neurotraumaBerlinARDS2005229.0 (19.5 IQR)50 (96.2%)Gender, injury severity scale, Glasgow coma scaleWithin 24 h following injuryAmat 2000 \[[@CR26]\]Case-controlCritically illAECCARDS352154 ± 1615 (71.4%)Not specifiedAt ICU admissionBai 2017 \[[@CR27]\]Prospective cohortCritically ill neurotraumaBerlinARDS502148 (39--57 IQR)10 (46.7%)Age, gender, BMI, injury score, blood transfusion, mechanical ventilation, Marshall CT score, Glasgow coma scaleAt admissionBai 2017 \[[@CR27]\]Prospective cohortCritically ill traumaBerlinARDS421644 (35--56 IQR)10 (62.5%)Age, gender, BMI, injury score, blood transfusion, mechanical ventilation, Marshall CT score, Glasgow coma scaleAt admissionBai 2018 \[[@CR28]\]Prospective cohortStroke patientsBerlinARDS3846064 (43--72 IQR)22 (36.7%)Age, gender, BMI, onset to treatment time, medical historyWithin 6 h following strokeChen 2019 \[[@CR29]\]Case-controlCritically ill sepsisBerlinARDS1155756.3 ± 10.140 (70.2%)Age, gender, BMI, smoking history, COPD, cardiomyopathy, APACHE II score, SOFA scoreWithin 24 h following ARDS onset or ICU admissionDu 2016 \[[@CR30]\]Prospective cohortCardiac surgery patientsAECCALI701857.7 ± 11.612 (66.7%)Age, medical history, BMI, systolic blood pressureWithin 1 h following surgeryFaust 2020 \[[@CR31]\]Prospective cohortCritically ill traumaBerlinARDS2244144 (30--60 IQR)37 (90.2%)Injury severity score, blunt mechanism, pre-ICU shockAt EDFaust 2020 \[[@CR31]\]Prospective cohortCritically ill sepsisBerlinARDS1204562 (52--67 IQR)15 (33.3%)Lung source of sepsis, shock, ageAt EDFremont 2010 \[[@CR32]\]Case-controlCritically illAECCALI/ARDS19210739 (26--53 IQR)71 (66.4%)Not specifiedWithin 72 h following ICU admissionGaudet 2018 \[[@CR33]\]Prospective cohortCritically ill patientsBerlinARDS721156 (51--63 IQR)8 (72.7%)Not specifiedAt inclusionHendrickson 2018 \[[@CR34]\]Retrospective cohortSevere traumatic brain injuryBerlinARDS1825044 ± 2042 (84.0%)Age, acute injury scale, Glasgow coma scale, vasopressor useWithin 10 min following ED arrivalHuang 2019 \[[@CR35]\]Prospective cohortCritically ill sepsisBerlinARDS1524163.2 ± 11.032 (78.0%)Age, gender, BMI, smoking history, COPD, cardiomyopathy, APACHE II score, SOFA scoreWithin 24 h following ICU admissionHuang 2019 \[[@CR36]\]Prospective cohortCritically ill pancreatitisBerlinARDS193314349 (42--60 IQR)87 (60.8%)Age, gender, aetiology of ARDS, APACHE II scoreAt admissionJabaudon 2018 \[[@CR37]\]Prospective cohortCritically illBerlinARDS4645962 ± 1646 (78.0%)SAPS II, sepsis, shock, pneumoniaWithin 6 h following ICU admissionJensen 2016 \[[@CR38]\]RCT (PASS)Critically illBerlinARDS40531NRNRAge, gender, APACHE II score, sepsis, eGFRWithin 24 h following admissionJensen 2016 \[[@CR38]\]RCT (PASS)Critically illBerlinARDS353\*31NRNRAge, gender, APACHE II score, sepsis, eGFRWithin 24 h following admissionJones 2020 \[[@CR39]\]Prospective cohortCritically ill sepsisBerlinARDS67226160 (51--69 IQR)154 (59.0%)Pulmonary source, APACHE III scoreAt admissionJones 2020 \[[@CR39]\]Prospective cohortCritically ill sepsisBerlinARDS843NRNRNRPulmonary source, APACHE III scoreWithin 48 h following admissionKomiya 2011 \[[@CR40]\]Cross sectionalAcute respiratory failureAECCALI/ARDS1245378 (69--85 IQR)34 (64.2%)Age, systolic blood pressure, VEF, chest X-ray pleural effusionWithin 2 h following emergency department arrivalLee 2011 \[[@CR41]\]Prospective cohortCritically illAECCALI/ARDS1135057.6 ± 19.124 (48.0%)Sepsis, BMIWithin 24 h following ICU admissionLin 2017 \[[@CR42]\]Retrospective cohortCritically illBerlinARDS2128354.3 ± 20.353 (63.9%)CRP, albumin, serum creatinine, APACHE II scoreWithin 2 h following ICU admissionLiu 2017 \[[@CR43]\]Prospective cohortCritically illAECCALI/ARDS1341969 ± 1810 (52.6%)APACHE II, sepsis severityOn arrival at EDLuo 2017 \[[@CR44]\]Retrospective cohortSevere pneumoniaAECCALI/ARDS1574356 ± 1925 (58.1%)Lung injury score, SOFA score, PaO~2~/FiO~2~, blood ureaDay 1 following admissionMeyer 2017 \[[@CR45]\]Prospective cohortCritically ill traumaBerlinARDS19810060 ± 1462 (62.0%)APACHE III score, age, gender, ethnicity, pulmonary infectionOn arrival at ED or ICUMikkelsen 2012 \[[@CR46]\]Case-controlCritically illAECCALI/ARDS482438 ± 2022 (91.7%)APACHE III scoreIn EDOsaka 2011 \[[@CR47]\]Prospective cohortPneumoniaAECCALI/ARDS27675 (51--92 range)4 (66.7%)Not specified3 to 5 days following admissionPalakshappa 2016 \[[@CR48]\]Prospective cohortCritically illBerlinARDS1637358 (52--68 IQR)42 (57.5%)APACHE III score, diabetes, BMI, pulmonary sepsisAt ICU admissionReilly 2018 \[[@CR49]\]Prospective cohortCritically ill sepsisBerlinARDS70328960 (51--69 IQR)170 (58.8%)Pulmonary source, APACHE III scoreWithin 24 h of ICU admissionShashaty 2019 \[[@CR50]\]Prospective cohortCritically ill sepsisBerlinARDS1204461 (50--68 IQR)NRAge, transfusion, pulmonary source, shockAt EDShashaty 2019 \[[@CR50]\]Prospective cohortCritically ill traumaBerlinARDS1803741 (25--62 IQR)NRInjury severity score, blunt mechanism, transfusionAt presentationShaver 2017 \[[@CR51]\]Prospective cohortCritically illAECCARDS2809054 (44--64 IQR)54 (60.0%)Age, APACHE II, sepsisDay of inclusionSuzuki 2017 \[[@CR52]\]Retrospective cohortSuspected drug-induced lung injuryNew bilateral lung infiltrationALI/ARDS683972 (65-81IQR)25 (64.1%)Gender, age, smoking history, biomarkersAs soon as possible after DLI suspicionWang 2019 \[[@CR53]\]Prospective cohortCritically ill sepsisBerlinARDS1093258 ± 10.7NRAge, gender, BMI, smoking history, COPD, cardiomyopathy, APACHE II score, SOFA scoreWithin 24 h following admissionWare 2017 \[[@CR54]\]Prospective cohortCritically ill trauma patientsBerlinARDS3937842 (26--55)56 (71.8%)Not specifiedWithin 24 h following inclusionXu 2018 \[[@CR55]\]Prospective cohortCritically illBerlinARDS1584560.0 ± 17.135 (77.8%)APACHE II score, Lung injury prediction score, biomarkers, sepsisWithin 24 h of ICU admissionYeh 2017 \[[@CR56]\]Prospective cohortCritically illAECCALI/ARDS1291865 ± 1810 (55.6%)APACHE II scoreOn arrival at the EDYing 2019 \[[@CR57]\]Prospective cohortCritically ill pneumoniaBerlinARDS1453761.3 ± 10.423 (62.2%)Age, SOFA score, lung injury score, heart rateAt admission**Total**^†^10,667241924.6%\*Validating cohort^†^Some studies included patients from the same cohort*Abbreviations*: *AECC* American European Consensus Conference definition of ARDS, *ALI* acute lung injury, *APACHE* acute physiology and chronic health evaluation, *ARDS* acute respiratory distress syndrome, *BMI* body mass index, *COPD* chronic obstructive pulmonary disease, *CRP C*-reactive protein, *DLI* drug-induced lung injury, *ED* emergency department, *eGFR* estimated glomerular filtration rate, *ICU* intensive care unit, *LVEF* left ventricular ejection fraction, *SAPS* simplified acute physiology score, *SOFA* sequential organ failure assessment

The study characteristics of the 53 studies for ARDS mortality are presented in Table [2](#Tab2){ref-type="table"}. A total of 15,344 patients with ARDS were included with an observed mortality rate of 36.0%. The AECC definition of ARDS was used in the majority of included studies (39/53). The included biomarkers were measured in plasma, bronchoalveolar lavage fluid, and urine. All samples were taken within 72 h following the development of ARDS. Table 2Study characteristics for ARDS mortalityStudyStudy designSettingARDS definitionOutcomeTotal (***n***)Non-survivors (***n***)AgeGender, male ***n*** (%)Variables in multivariate analysisSample momentAdamzik 2013 \[[@CR58]\]Prospective cohortSingle centreAECC30 days471744 ± 1332 (68. 1%)SAPS II score, gender, lung injury score, ECMO, CVVHD, BMI, CRP, procalcitoninWithin 24 h following ICU admissionAhasic 2012 \[[@CR24]\]Prospective cohortMulticentreAECC60 days1757860.7 ± 17.6102 (58.3%)Gender, BMI, cirrhosis, Diabetes, need for red cell transfusion, sepsis, septic shock, traumaWithin 48 h following ICU admissionAmat 2000 \[[@CR26]\]Prospective cohortTwo centreAECC ARDS1 month after ICU discharge211154 ± 1615 (71.4%)Not specifiedDay 0 ICUBajwa 2008 \[[@CR59]\]Prospective cohortSingle centreAECC60 day1777068.3 ± 15.399 (55.9%)APACHE III scoreWithin 48 h following ARDS onsetBajwa 2009 \[[@CR60]\]Prospective cohortSingle centreAECC60 days1777062.5 (IQR 29.0)100 (56.5%)APACHE III scoreWithin 48 h following ARDS onsetBajwa 2013 \[[@CR61]\]RCT (FACTT)MulticentreAECC60 days826NR48 (38--59 IQR)442 (53.5%)APACHE III scoreDays 0 and 3Calfee 2008 \[[@CR62]\]RCT (ARMA)MulticentreAECC180 days676NR51 ± 17282 (41.7%)Age, gender, APACHE III score, sepsis, or traumaDay 0Calfee 2009 \[[@CR63]\]RCT (ARMA)MulticentreAECCHospital77827251 ± 17459 (59.0%)Age, PaO~2~/FiO~2~, APACHE III score, sepsis or traumaDay 0Calfee 2011 \[[@CR64]\]RCT (ARMA)MulticentreAECC90 days54718650 ± 16227 (41.5%)APACHE III score, tidal volumeDay 0Calfee 2012 \[[@CR65]\]RCT (FACTT)MulticentreAECC90 days93126150 ± 16498 (53.5%)Age, APACHE III score, fluid management strategyDay 0Calfee 2015 \[[@CR66]\]Prospective cohortSingle centreAECCHospital1003158 ± 1152 (52.0%)APACHE III scoreDay 2 following ICU admissionCalfee 2015 \[[@CR66]\]RCT (FACTT)MulticentreAECC90 days85325951 ± 15444 (52.1%)APACHE III scoreWithin 48 h following ARDS onsetCartin-Ceba 2015 \[[@CR67]\]Prospective cohortSingle centreAECCIn-hospital1003662.5 (51--75 IQR)54 (54.0%)Acute physiology score of APACHE III score, DNR status, McCabe scoreWithin 24 h following diagnosisChen 2009 \[[@CR68]\]Prospective cohortSingle centre\*28 days592662 ± 1935 (59.3%)APACHE II score, biomarkersWithin 24 h following diagnosisClark 1995 \[[@CR69]\]Prospective cohortSingle centre\*\*Mortality1174843.4 ± 15.475 (64.1%)Lung injury score, risk factor for ARDS, lavage protein concentrationDay 3 following disease onsetClark 2013 \[[@CR70]\]RCT (FACTT)MulticentreAECC60 days40010647 (37--57 IQR)210 (52.5%)Age, gender, ethnicity, baseline serum creatinine, ARDS risk factorDay 1 following inclusionDolinay 2012 \[[@CR71]\]Prospective cohortSingle centreAECCIn-hospital281754 ± 14.513 (46.4%)APACHE II scoreWithin 48 h following ICU admissionEisner 2003 \[[@CR72]\]RCT (ARMA)MulticentreAECC180 days56519551 ± 17332 (58.8%)Ventilation strategy, APACHE III score, PaO~2~/FiO~2~, creatinine, platelet countDay 0 following inclusionForel 2015 \[[@CR73]\]Prospective cohortMulticentrerBerlin \< 200 mmHgICU51NR (for ICU)60 ± 1340 (78.4%)Lung injury scoreDay 3Forel 2018 \[[@CR74]\]Prospective cohortSingle centreBerlin \< 200 mmHg60 days622159 ± 1547 (75.8%)Gender, SOFA score, LIS scoreDay 3 following onset of ARDSGuervilly 2011 \[[@CR75]\]Prospective cohortSingle centreAECC28 days522158 ± 1739 (75.0%)Not specifiedWithin 24 h following diagnosisKim 2019 \[[@CR76]\]Retrospective cohortSingle centreBerlinIn-hospital976367.2 (64.3--70.1)63 (64.3%)APACHE II score, SOFA score, SAPS II scoreWithin 48 h following admissionLee 2019 \[[@CR77]\]Retrospective cohortSingle centreBerlinIn-hospital23715469 (61--74 IQR)166 (70.0%)Age, diabetes mellitus, non-pulmonary source, APACHE II score, SOFAWithin 24 h following intubationLesur 2006 \[[@CR78]\]Prospective cohortMulticentreAECC28 days782963 ± 1648 (61.5%)Age, PaCO~2~, APACHE II scoreWithin 48 h following onset of ARDSLi 2019 \[[@CR79]\]Retrospective cohortSingle centreBerlin28 days2247064 (46--77 IQR)140 (62.5%)APACHE II score, age, gender, BMI, smoking status, alcohol abusing status, risk factors, comorbiditiesWithin 24 h following ICU admissionLin 2010 \[[@CR80]\]Prospective cohortSingle centreAECC ARDS28 days632775 (57--83 IQR)38 (60.3%)Age, lung injury score, SOFA score, APACHE II score, CRP, biomarkersWithin 24 h following ARDS onsetLin 2012 \[[@CR81]\]Prospective cohortSingle centreAECC30 days872761 (56--70 IQR)42 (48.3%)APACHE II, Lung injury score, creatinine, biomarkersAt inclusionLin 2013 \[[@CR82]\]Prospective cohortSingle centreAECC30 days782263 (54--68 IQR)45 (57.7%)Age, APACHE II score, Lung injury score, PaO~2~/FiO~2~Within 10 h following diagnosisMadtes 1998 \[[@CR83]\]Prospective cohortSingle centre\*\*\*In-hospital743338 (19--68 Range)50 (67.6%)Age, PCP III levels, neutrophils, lung injury scoreDay 3 following ARDS onsetMcClintock 2006 \[[@CR84]\]RCT (ARMA)MulticentreAECCMortality579NR51 ± 17333 (57.5%)Ventilator group assignmentDay 0 following inclusionMcClintock 2007 \[[@CR85]\]RCT (ARMA)MulticentreAECCMortality576NR52 ± 17328 (56.9%)Gender, ventilator group assignment, eGFR, age, APACHE III score, vasopressor use, sepsisDay 0 following inclusionMcClintock 2008 \[[@CR86]\]Prospective cohortTwo centreAECCIn-hospital502155 ± 1628 (56.0%)Age, gender, SAPS IIWithin 48 h following diagnosisMenk 2018 \[[@CR87]\]Retrospective cohortSingle centreBerlinICU40418250 (37--61 IQR)265 (65.6%)Age, gender, APACHE II score, SOFA, severe ARDS, peak airway pressure, pulmonary complianceWithin 24 h following admissionMetkus 2017 \[[@CR88]\]RCT (ALVEOLI, FACTT)MulticentreAECC60 days1057NR50.4549 (51.9%)Age, gender, trial group assignmentWithin 24 h following inclusionMrozek 2016 \[[@CR89]\]Prospective cohortMulticentreAECC90 days1194257 ± 1782 (68.9%)Age, gender, SAPS II score, PaO~2~/FiO~2,~ sepsisWithin 24 h following inclusionOng 2010 \[[@CR90]\]Prospective cohortTwo centreAECC28-day in-hospital24NR51 ± 2130 (53.6%)Age, gender, PaO~2~/FiO~2~, tidal volume, plateau pressure, APACHE II scoreAt inclusionParsons 2005 \[[@CR91]\]RCT (ARMA)MulticentreAECC180 days or discharge562196NRNRVentilation strategy, APACHE III score, PaO~2~/FiO~2~, creatinine, platelet count, vasopressor useAt inclusionParsons 2005 \[[@CR92]\]RCT (ARMA)MulticentreAECCIn-hospital78127651.6 ± 17.3319 (40.1%)Ventilation strategy, APACHE III score, PaO~2~/FiO~2~, creatinine, platelet count, vasopressor useDay 0Quesnel 2012 \[[@CR93]\]Prospective cohortSingle centreAECC28 days923767 (49--74 IQR)61 (66.3%)Age, SAPS II score, malignancy, SOFA score, BAL characteristicsNRRahmel 2018 \[[@CR94]\]Retrospective cohortSingle centreAECC30 days1193743.7 ± 13.371 (59.7%)Age, SOFA scoreWithin 24 h following admissionReddy 2019 \[[@CR95]\]Prospective cohortSingle centreBerlin30 days391955 (47.5-61.5)25 (64.1%)Not specifiedWithin 24 h of ARDS diagnosisRivara 2012 \[[@CR96]\]Prospective cohortSingle centreAECC60 days1777071.5 (59--80 IQR)98 (55.4%)APACHE III scoreWithin 48 h following diagnosisRogers 2019 \[[@CR97]\]RCT (SAILS)MulticentreAECC60 days683NR56 (43--65)335 (49.0%)Age, race, APACHE III score, GFR, randomization, shockWithin 48 h following ARDS diagnosisSapru 2015 \[[@CR98]\]RCT (FACTT)MulticentreAECC60 days44910949.8 ± 15.6242 (53.9%)Age, gender, APACHE III score, pulmonary sepsis, fluid management strategyUpon inclusionSuratt 2009 \[[@CR99]\]RCT (ARMA)MulticentreAECCIn-hospital64522251 ± 17381 (59.1%)Ventilation strategy, age, genderDay 0Tang 2014 \[[@CR100]\]Prospective cohortMulticentreBerlinIn-hospital422072.5 ± 10.827 (64.3%)APACHE II score, PaO~2~/FiO~2~, CRP, WBC, procalcitoninWithin 24 h following diagnosisTsangaris 2009 \[[@CR101]\]Prospective cohortSingle centreAECC28 days522766.1 ± 16.932 (59.6%)APACHE II score, age, genotypeWithin 48 h following admissionTsangaris 2017 \[[@CR102]\]Prospective cohortSingle centreNR28 days532864.6 ± 16.833 (62.3%)Lung injury scoreWithin 48 h following diagnosisTsantes 2013 \[[@CR103]\]Prospective cohortSingle centreAECC28 days693464.4 ± 17.943 (62.3%)Age, gender, APACHE II score, SOFA score, pulmonary parameters, serum lactateWithin 48 h following diagnosisTseng 2014 \[[@CR104]\]Prospective cohortSingle centreAECC ARDSICU561670.6 ± 9.231 (55.4%)APACHE II score, SOFA score, SAPS II scoreDay 1 following ICU admissionWang 2017 \[[@CR105]\]Prospective cohortMulticentreBerlin60 days1676276.5 (19--95 range)112 (67.1%)Age, gender, APACHE II scoreDay 1 following diagnosisWang 2018 \[[@CR106]\]Retrospective cohortSingle centreAECCMortality24714662 (48--73 IQR)162 (65.6%)Age, cirrhosis, creatinine, PaO~2~/FiO~2~Within 24 h following diagnosisWare 2004 \[[@CR107]\]RCT (ARMA)MulticentreAECCIn-hospital55919351 ± 17332 (59.4%)Ventilator strategy, APACHE III score, PaO~2~/FiO~2~, creatinine, platelet countDay 0 of inclusionXu 2017 \[[@CR108]\]Retrospective cohortSingle centreBerlin28 days632754 (42--67 IQR)37 (58.7%)APACHE II score, PaO~2~/FiO~2~, procalcitoninWithin 48 following admission**Total**^†^15,344391436.0%\*Respiratory failure requiring positive pressure ventilation, PF ratio \< 200 mmHg, bilateral pulmonary infiltration on chest X-ray, no clinical evidence of left atrial hypertension\*\*PF ratio \< 150 mmHg, PF \< 200 mmHg with 5 PEEP, diffuse parenchymal infiltrates, pulmonary artery wedge pressure \< 18 mmHg, no clinical evidence of congestive heart failure\*\*\*PF ratio \< 150 mmHg, PF ratio \< 200 mmHg with 5 cmH2O PEEP, diffuse parenchymal infiltrates, pulmonary artery wedge pressure \< 18 mmHg, or no clinical evidence of congestive heart failure^†^Some studies included patients from the same cohort*Abbreviations*: *AECC* American European Consensus Conference definition of ARDS, *APACHE* acute physiology and chronic health evaluation, *ARDS* acute respiratory distress syndrome, *BAL* bronchoalveolar lavage, *BMI* body mass index, *CRP* C-reactive protein, *CVVHD* continuous veno-venous haemodialysis, *DNR* do not resuscitate, *ECMO* extra corporeal membrane oxygenation, *eGFR* estimated glomerular filtration rate, *FiO*~*2*~ fraction of inspired oxygen, *ICU* intensive care unit, *PCP* procollagen, *No*. number, *SAPS* simplified acute physiology score, *SOFA* sequential organ failure assessment, *WBC* white blood cell count

The median quality of the included publications according to the NOS was 7 (range 4--9) for ARDS development and 8 (range 5--9) for ARDS mortality (Additional file [2](#MOESM2){ref-type="media"}).

Biomarkers associated with ARDS development in the at-risk population {#Sec10}
---------------------------------------------------------------------

A total of 37 biomarkers in plasma, 7 in cerebrospinal fluid, and 1 in bronchoalveolar lavage fluid were assessed in multivariate analyses (Table [3](#Tab3){ref-type="table"}). Five studies examined angiopoeitin-2 (Ang-2) and seven studies examined receptor for advanced glycation end products (RAGE). In all studies, high plasma levels of Ang-2 and RAGE were significantly associated with an increased risk of ARDS development in the at-risk population. Similar results were seen for surfactant protein D (SpD) in plasma in all three studies that assessed SpD. In contrast, biomarkers for inflammation as C-reactive protein (CRP), procalcitonin, interleukin-6, and interleukin-8 were not clearly associated with ARDS development. The majority of biomarkers in plasma are surrogates for inflammation in ARDS pathophysiology (Fig. [2](#Fig2){ref-type="fig"}). Table 3Risk ratios for ARDS development in the at-risk populationReferenceBiomarker role in ARDSSample sizeRisk ratio (95% CI)Cut-offComment**Biomarkers in plasma** AdiponectinPalakshappa 2016 \[[@CR48]\]Anti-inflammatory1631.12 (1.01--1.25)Per 5 mcg/mL Angiopoietin-2Agrawal 2013 \[[@CR23]\]Increased endothelial permeability1671.8 (1.0--3.4)Per log10 Angiopoietin-2Fremont 2010 \[[@CR32]\]Increased endothelial permeability1922.20 (1.19--4.05)Highest vs lowest quartile Angiopoietin-2Reilly 2018 \[[@CR49]\]Increased endothelial permeability7031.49 (1.20--1.77)Per log increase Angiopoietin-2Ware 2017 \[[@CR54]\]Increased endothelial permeability3931.890 (1.322--2.702)1st vs 4th quartile Angiopoietin-2Xu 2018 \[[@CR55]\]Increased endothelial permeability1581.258 (1.137--1.392) Advanced oxidant protein productsDu 2016 \[[@CR30]\]Oxidative injury701.164 (1.068--1.269) Brain natriuretic peptideFremont 2010 \[[@CR32]\]Myocardial strain1920.45 (0.26--0.77)Highest vs lowest quartile Brain natriuretic peptideKomiya 2011 \[[@CR40]\]Myocardial strain12414.425 (4.382--47.483)\> 500 pg/mLOutcome is CPE Club cell secretory proteinJensen 2016 \[[@CR38]\]Alveolar epithelial injury4052.6 (0.7--9.7)≥ 42.8 ng/mLLearning cohort Club cell secretory proteinJensen 2016 \[[@CR38]\]Alveolar epithelial injury3530.96 (0.20--4.5)≥ 42.8 ng/mLValidating cohort Club cell secretory proteinLin 2017 \[[@CR42]\]Alveolar epithelial injury2121.096 (1.085--1.162) C-reactive protein (CRP)Bai 2018 \[[@CR28]\]Inflammation3841.314 (0.620--1.603) C-reactive protein (CRP)Chen 2019 \[[@CR29]\]Inflammation1150.994 (0.978--1.010) C-reactive protein (CRP)Huang 2019 \[[@CR35]\]Inflammation1521.287 (0.295--5.606)≥ 90.3 mg/L C-reactive protein (CRP)Huang 2019 \[[@CR36]\]Inflammation19331.008 (1.007--1.010) C-reactive protein (CRP)Komiya 2011 \[[@CR40]\]Inflammation1240.106 (0.035--0.323)\> 50 mg/LOutcome is CPE C-reactive protein (CRP)Lin 2017 \[[@CR42]\]Inflammation2121.007 (1.001--1.014) C-reactive protein (CRP)Osaka 2011 \[[@CR47]\]Inflammation271.029 (0.829--1.293)Per 1 mg/dL increase C-reactive protein (CRP)Wang 2019 \[[@CR53]\]Inflammation1091.000 (0.992--1.008) C-reactive protein (CRP)Ying 2019 \[[@CR57]\]Inflammation1451.22 (0.95--1.68) Free 2-chlorofatty acidMeyer 2017 \[[@CR45]\]Oxidative injury1981.62 (1.25--2.09)Per log10 Total 2-chlorofatty acidMeyer 2017 \[[@CR45]\]Oxidative injury1981.82 (1.32--2.52)Per log10 Free 2-chlorostearic acidMeyer 2017 \[[@CR45]\]Oxidative injury1981.82 (1.41--2.37)Per log10 Total 2-chlorostearic acidMeyer 2017 \[[@CR45]\]Oxidative injury1981.78 (1.31--2.43)Per log10 EndocanGaudet 2018 \[[@CR33]\]Leukocyte adhesion inhibition720.001 (0--0.215)\> 5.36 ng/mL EndocanMikkelsen 2012 \[[@CR46]\]Leukocyte adhesion inhibition480.69 (0.49--0.97)1 unit increase EndocanYing 2019 \[[@CR57]\]Leukocyte adhesion modulation1451.57 (1.14--2.25) FibrinogenLuo 2017 \[[@CR44]\]Coagulation1571.893 (1.141--3.142) GlutamateBai 2017 \[[@CR27]\]Non-essential amino acid, neurotransmitter502.229 (1.082--2.634) GlutamateBai 2017 \[[@CR27]\]Non-essential amino acid, neurotransmitter420.996 (0.965--1.028) GlutamateBai 2018 \[[@CR28]\]Non-essential amino acid3843.022 (2.001--4.043) Growth arrest-specific gene 6Yeh 2017 \[[@CR56]\]Endothelial activation1291.6 (1.3--2.6) Insulin-like growth factor 1Ahasic 2012 \[[@CR24]\]Pro-fibrotic5310.58 (0.42--0.79)Per log10 IGF binding protein 3Ahasic 2012 \[[@CR24]\]Pro-fibrotic5310.57 (0.40--0.81)Per log10 Interleukin-1 betaAisiku 2016 \[[@CR25]\]Pro-inflammatory1940.98 (0.73--1.32) Interleukin-1 betaChen 2019 \[[@CR29]\]Pro-inflammatory1151.001 (0.945--1.061) Interleukin-1 betaHuang 2019 \[[@CR35]\]Pro-inflammatory1520.666 (0.152--2.910)≥ 11.3 pg/mL Interleukin-1 betaWang 2019 \[[@CR53]\]Pro-inflammatory1091.021 (0.982--1.063) Interleukin-6Aisiku 2016 \[[@CR25]\]Pro-inflammatory1951.24 (1.05--1.49) Interleukin-6Bai 2018 \[[@CR28]\]Pro-inflammatory3841.194 (0.806--1.364) Interleukin-6Chen 2019 \[[@CR29]\]Pro-inflammatory1150.998 (0.993--1.003) Interleukin-6Huang 2019 \[[@CR35]\]Pro-inflammatory1520.512 (0.156--1.678)≥ 63.7 pg/mL Interleukin-6Yeh 2017 \[[@CR56]\]Pro-inflammatory1291.4 (0.98--1.7) Interleukin-8Agrawal 2013 \[[@CR23]\]Pro-inflammatory1671.3 (0.97--1.8)Per log10 Interleukin-8Aisiku 2016 \[[@CR25]\]Pro-inflammatory1941.26 (1.04--1.53) Interleukin-8Chen 2019 \[[@CR29]\]Pro-inflammatory1151.000 (0.996--1.003) Interleukin-8Fremont 2010 \[[@CR32]\]Pro-inflammatory1921.81 (1.03--3.17)Highest vs lowest quartile Interleukin-8Liu 2017 \[[@CR43]\]Pro-inflammatory1341.4 (0.98--1.7)Per log10 Interleukin-8Yeh 2017 \[[@CR56]\]Pro-inflammatory1291.4 (0.92--1.7) Interleukin-10Aisiku 2016 \[[@CR25]\]Anti-inflammatory1951.66 (1.22--2.26) Interleukin-10Chen 2019 \[[@CR29]\]Anti-inflammatory1151.003 (0.998--1.018) Interleukin-10Fremont 2010 \[[@CR32]\]Anti-inflammatory1922.02 (0.96--4.25)Highest vs lowest quartile Interleukin-12p70Aisiku 2016 \[[@CR25]\]Pro-inflammatory1941.18 (0.82--1.69) Interleukin-17Chen 2019 \[[@CR29]\]Pro-inflammatory1151.003 (1.000--1.007)Not significant Interleukin-17Huang 2019 \[[@CR35]\]Pro-inflammatory1520.644 (0.173--2.405)≥ 144.55 pg/mL Interleukin-17Wang 2019 \[[@CR53]\]Pro-inflammatory1091.001 (0.997--1.004) Leukotriene B4Amat 2000 \[[@CR26]\]Pro-inflammatory3514.3 (2.3--88.8)\> 14 pmol/mL MicroparticlesShaver 2017 \[[@CR51]\]Coagulation2800.693 (0.490--0.980)Per 10 μM Mitochondrial DNAFaust 2020 \[[@CR31]\]Damage-associated molecular pattern2241.58 (1.14--2.19)48 h plasma Mitochondrial DNAFaust 2020 \[[@CR31]\]Damage-associated molecular pattern1201.52 (1.12--2.06)Per log copies per microlitre48 h plasma MyeloperoxidaseMeyer 2017 \[[@CR45]\]Pro-inflammatory1981.28 (0.89--1.84)Per log10 Nitric oxideAisiku 2016 \[[@CR25]\]Oxidative injury1931.60 (0.98--2.90) Parkinson disease 7Liu 2017 \[[@CR43]\]Anti-oxidative injury1341.8 (1.1--3.5)Per log10 Pre B cell colony enhancing factorLee 2011 \[[@CR41]\]Pro-inflammatory1130.78 (0.43--1.41)Per 10 fold increase ProcalcitoninBai 2018 \[[@CR28]\]Inflammation3841.156 (0.844--1.133) ProcalcitoninChen 2019 \[[@CR29]\]Inflammation1151.020 (0.966--1.077) ProcalcitoninHuang 2019 \[[@CR35]\]Inflammation1522.506 (0.705--8.913)≥ 13.2 ng/mL ProcalcitoninHuang 2019 \[[@CR36]\]Inflammation19331.008 (1.000--1.016)Not significant ProcalcitoninWang 2019 \[[@CR53]\]Inflammation1091.019 (0.981--1.058) Procollagen IIIFremont 2010 \[[@CR32]\]Pro-fibrotic1922.90 (1.61--5.23)Highest vs lowest quartile Receptor for advanced glycation end productsFremont 2010 \[[@CR32]\]Alveolar epithelial injury1923.33 (1.85--5.99)Highest vs lowest quartile Receptor for advanced glycation end productsJabaudon 2018 \[[@CR37]\]Alveolar epithelial injury4642.25 (1.60--3.16)Per log10Baseline Receptor for advanced glycation end productsJabaudon 2018 \[[@CR37]\]Alveolar epithelial injury4644.33 (2.85--6.56)Per log10Day 1 Receptor for advanced glycation end productsJones 2020 \[[@CR39]\]Alveolar epithelial injury6721.73 (1.35--2.21)European ancestry Receptor for advanced glycation end productsJones 2020 \[[@CR39]\]Alveolar epithelial injury6722.05 (1.50--2.83)African ancestry Receptor for advanced glycation end productsJones 2020 \[[@CR39]\]Alveolar epithelial injury8432.56 (2.14--3.06)European ancestry Receptor for advanced glycation end productsWare 2017 \[[@CR54]\]Alveolar epithelial injury3932.382 (1.638--3.464)1st vs 4th quartile Receptor interacting protein kinase-3Shashaty 2019 \[[@CR50]\]Increased endothelial permeability1201.30 (1.03--1.63)Per 0.5 SD Receptor interacting protein kinase-3Shashaty 2019 \[[@CR50]\]Increased endothelial permeability1801.83 (1.35--2.48)Per 0.5 SD Soluble endothelial selectinOsaka 2011 \[[@CR47]\]Pro-inflammatory271.099 (1.012--1.260)Per 1 ng/mL increase Soluble urokinase plasminogen activator receptorChen 2019 \[[@CR29]\]Pro-inflammatory1151.131 (1.002--1.277) Surfactant protein DJensen 2016 \[[@CR38]\]Alveolar epithelial injury4053.4 (1.0--11.4)≥ 525.6 ng/mLLearning cohort Surfactant protein DJensen 2016 \[[@CR38]\]Alveolar epithelial injury3538.4 (2.0--35.4)≥ 525.6 ng/mLValidating cohort Surfactant protein DSuzuki 2017 \[[@CR52]\]Alveolar epithelial injury685.31 (1.40--20.15)Per log10 Tissue inhibitor of matrix metalloproteinase 3Hendrickson 2018 \[[@CR34]\]Decreases endothelial permeability1821.4 (1.0--2.0)1 SD increase Tumour necrosis factor alphaAisiku 2016 \[[@CR25]\]Pro-inflammatory1951.03 (0.71--1.51) Tumour necrosis factor alphaChen 2019 \[[@CR29]\]Pro-inflammatory1151.002 (0.996--1.009) Tumour necrosis factor alphaFremont 2010 \[[@CR32]\]Pro-inflammatory1920.51 (0.27--0.98)Highest vs lowest quartile Tumour necrosis factor alphaHuang 2019 \[[@CR35]\]Pro-inflammatory1523.999 (0.921--17.375)≥ 173.0 pg/mL Tumour necrosis factor alphaWang 2019 \[[@CR53]\]Pro-inflammatory1091.000 (0.995--1.005)**Biomarkers in CSF** Interleukin-1 betaAisiku 2016 \[[@CR25]\]Pro-inflammatory1741.11 (0.80--1.54) Interleukin-6Aisiku 2016 \[[@CR25]\]Pro-inflammatory1741.06 (0.95--1.19) Interleukin-8Aisiku 2016 \[[@CR25]\]Pro-inflammatory1731.01 (0.92--1.12) Interleukin-10Aisiku 2016 \[[@CR25]\]Anti-inflammatory1741.33 (1.00--1.76) Interleukin-12p70Aisiku 2016 \[[@CR25]\]Pro-inflammatory1731.52 (1.04--2.21) Nitric oxideAisiku 2016 \[[@CR25]\]Oxidative injury1721.66 (0.70--3.97) Tumour necrosis factor alphaAisiku 2016 \[[@CR25]\]Pro-inflammatory1741.43 (0.97--2.14)**Biomarkers in BALF** Soluble trombomodulinSuzuki 2017 \[[@CR52]\]Endothelial injury687.48 (1.60--34.98)*Abbreviations*: *CPE* cardiopulmonary effusion, *CSF* cerebrospinal fluid, *BALF* bronchoalveolar lavage fluid, *SD* standard deviationFig. 2Biomarker role in ARDS pathophysiology

Biomarkers associated with mortality in the ARDS population {#Sec11}
-----------------------------------------------------------

A total of 49 biomarkers in plasma, 8 in bronchoalveolar lavage fluid, and 3 in urine were included in this study (Table [4](#Tab4){ref-type="table"}). Ang-2, CRP, interleukin-8 (IL-8), RAGE, SpD, and Von Willebrand factor (VWF) in plasma were assessed in four or more studies. However, none of these biomarkers was associated with ARDS mortality in all four studies. Similarly to biomarkers in ARDS development, the majority of biomarkers for ARDS mortality in plasma had a pathophysiological role in inflammation (Fig. [2](#Fig2){ref-type="fig"}). The majority of biomarkers measured in bronchoalveolar lavage fluid had a pro-fibrotic role in ARDS pathophysiology. Table 4Risk ratios for ARDS mortality in the ARDS populationReferenceBiomarker role in ARDSSample sizeRisk ratio (95% CI)Cut-offComment**Biomarkers in plasma** Activin-AKim 2019 \[[@CR76]\]Pro-fibrotic972.64 (1.04--6.70) Angiopoietin-1/angiopoietin-2 ratioOng 2010 \[[@CR90]\]Modulates endothelial permeability245.52 (1.22--24.9) Angiopoietin-2Calfee 2012 \[[@CR65]\]Increased endothelial permeability9310.92 (0.73--1.16)Per log10Infection-related ALI Angiopoietin-2Calfee 2012 \[[@CR65]\]Increased endothelial permeability9311.94 (1.15--3.25)Per log10Noninfection-related ALI Angiopoietin-2Calfee 2015 \[[@CR66]\]Increased endothelial permeability1002.54 (1.38--4.68)Per log10Single centre Angiopoietin-2Calfee 2015 \[[@CR66]\]Increased endothelial permeability8531.43 (1.19--1.73)per log10Multicentre Angiotensin 1--9Reddy 2019 \[[@CR95]\]Pro-fibrotic392.24 (1.15--4.39)Concentration doubled (in Ln) Angiotensin 1--10Reddy 2019 \[[@CR95]\]Pro-fibrotic390.36 (0.18--0.72)Concentration doubled (in Ln) Angiotensin converting enzymeTsantes 2013 \[[@CR103]\]Endothelial permeability, pro-fibrotic691.06 (1.02--1.10)Per 1 unit increase28-day mortality Angiotensin converting enzymeTsantes 2013 \[[@CR103]\]Endothelial permeability, pro-fibrotic691.04 (1.01--1.07)Per 1 unit increase90-day mortality NT-pro brain natriuretic peptideBajwa 2008 \[[@CR59]\]Myocardial strain1772.36 (1.11--4.99)≥ 6813 ng/L NT-pro brain natriuretic peptideLin 2012 \[[@CR81]\]Myocardial strain872.18 (1.54--4.46)Per unit Club cell secretory proteinCartin-Ceba 2015 \[[@CR67]\]Alveolar epithelial injury1001.09 (0.60--2.02)Per log10 Club cell secretory proteinLesur 2006 \[[@CR78]\]Alveolar epithelial injury781.37 (1.25--1.83)Increments of 0.5 CopeptinLin 2012 \[[@CR81]\]Osmo-regulatory874.72 (2.48--7.16)Per unit C-reactive protein (CRP)Adamzik 2013 \[[@CR58]\]Inflammation471.01 (0.9--1.1)Per log10 C-reactive protein (CRP)Bajwa 2009 \[[@CR60]\]Inflammation1770.67 (0.52--0.87)Per log10 C-reactive protein (CRP)Lin 2010 \[[@CR80]\]Inflammation632.316 (0.652--8.226) C-reactive protein (CRP)Tseng 2014 \[[@CR104]\]Inflammation561.265 (0.798--2.005)Day 3 D-dimerTseng 2014 \[[@CR104]\]Coagulation561.211 (0.818--1.793) Decoy receptor 3Chen 2009 \[[@CR68]\]Immunomodulation594.02 (1.20--13.52)\> 1 ng/mLValidation cohort EndocanTang 2014 \[[@CR100]\]Leukocyte adhesion inhibition421.374 (1.150--1.641)\> 4.96 ng/mL EndocanTsangaris 2017 \[[@CR102]\]Leukocyte adhesion inhibition533.36 (0.74--15.31)\> 13 ng/mL Galectin 3Xu 2017 \[[@CR108]\]Pro-fibrotic631.002 (0.978--1.029)Per 1 ng/mL Granulocyte colony stimulating factorSuratt 2009 \[[@CR99]\]Inflammation6451.70 (1.06--2.75)Quartile 4 vs quartile 2 Growth differentiation factor-15Clark 2013 \[[@CR70]\]Pro-fibrotic4002.86 (1.84--4.54)Per log10 Heparin binding proteinLin 2013 \[[@CR82]\]Inflammation, endothelial permeability781.52 (1.12--2.85)Per log10 High mobility group protein B1Tseng 2014 \[[@CR104]\]Pro-inflammatory561.002 (1.000--1.004)Day 1 High mobility group protein B1Tseng 2014 \[[@CR104]\]Pro-inflammatory560.990 (0.968--1.013)Day 3 Insulin-like growth factorAhasic 2012 \[[@CR24]\]Pro-fibrotic1750.70 (0.51--0.95)Per log10 IGF binding protein 3Ahasic 2012 \[[@CR24]\]Pro-fibrotic1750.69 (0.50--0.94)Per log10 Intercellular adhesion molecule-1Calfee 2009 \[[@CR63]\]Pro-inflammatory7781.22 (0.99--1.49)Per log10 Intercellular adhesion molecule-1Calfee 2011 \[[@CR64]\]Pro-inflammatory5470.74 (0.59--0.95)Per natural log Intercellular adhesion molecule-1McClintock 2008 \[[@CR86]\]Pro-inflammatory505.8 (1.1--30.0)Per natural log Interleukin-1 betaLin 2010 \[[@CR80]\]Pro-inflammatory631.355 (0.357--5.140)Per log 10 Interleukin-6Calfee 2015 \[[@CR66]\]Pro-inflammatory1001.81 (1.34--2.45)Per log10Single centre Interleukin-6Calfee 2015 \[[@CR66]\]Pro-inflammatory8531.24 (1.14--1.35)Per log10Multicentre Interleukin-6Parsons 2005 \[[@CR92]\]Pro-inflammatory7811.18 (0.93--1.49)Per log10 Interleukin-8Amat 2000 \[[@CR26]\]Pro-inflammatory210.09 (0.01--1.35)\> 150 pg/mL Interleukin-8Calfee 2011 \[[@CR64]\]Pro-inflammatory5471.36 (1.15--1.62)Per natural log Interleukin-8Calfee 2015 \[[@CR66]\]Pro-inflammatory1001.65 (1.25--2.17)Per log10Single centre Interleukin-8Calfee 2015 \[[@CR66]\]Pro-inflammatory8531.41 (1.27--1.57)Per log10Multicentre Interleukin-8Cartin-Ceba 2015 \[[@CR67]\]Pro-inflammatory1001.08 (0.72--1.61)Per log10 Interleukin-8Lin 2010 \[[@CR80]\]Pro-inflammatory630.935 (0.280--3.114)Per log 10 Interleukin-8McClintock 2008 \[[@CR86]\]Pro-inflammatory502.0 (1.1--4.0)Per natural log Interleukin-8Parsons 2005 \[[@CR92]\]Pro-inflammatory7801.73 (1.28--2.34)Per log10 Interleukin-8Tseng 2014 \[[@CR104]\]Pro-inflammatory561.039 (0.955--1.130)Day 1 Interleukin-8Tseng 2014 \[[@CR104]\]Pro-inflammatory561.075 (0.940--1.229)Day 3 Interleukin-10Parsons 2005 \[[@CR92]\]Anti-inflammatory5931.23 (0.86--1.76)Per log10 Interleukin-18Dolinay 2012 \[[@CR71]\]Pro-inflammatory281.60 (1.17--2.20)Per 500 pg/mL increase Interleukin-18Rogers 2019 \[[@CR97]\]Pro-inflammatory6832.2 (1.5--3.1)≥ 800 pg/mL Leukocyte microparticlesGuervilly 2011 \[[@CR75]\]Immunomodulation525.26 (1.10--24.99)\< 60 elements/μL Leukotriene B4Amat 2000 \[[@CR26]\]Pro-inflammatory2122.5 (1.1--460.5)\> 14 pmol/mL Neutrophil elastaseWang 2017 \[[@CR105]\]Pro-inflammatory1671.76 (*p* value 0.002)1 SD changeDay 1 Neutrophil elastaseWang 2017 \[[@CR105]\]Pro-inflammatory1671.58 (*p* value 0.06)1 SD changeDay 3 Neutrophil elastaseWang 2017 \[[@CR105]\]Pro-inflammatory1671.70 (*p* value 0.001)1 SD changeDay 7 Neutrophil to lymphocyte ratioLi 2019 \[[@CR79]\]Pro-inflammatory2245.815 (1.824--18.533)First--fourth quartile Neutrophil to lymphocyte ratioWang 2018 \[[@CR106]\]Pro-inflammatory2471.011 (1.004--1.017)Per 1% increase Neutrophil to lymphocyte ratioWang 2018 \[[@CR106]\]Pro-inflammatory2471.532 (1.095--2.143)\> 14 Nucleated red blood cellsMenk 2018 \[[@CR87]\]Erythrocyte progenitor cell, pro-inflammatory4043.21 (1.93--5.35)\> 220/μL Peptidase inhibitor 3Wang 2017 \[[@CR105]\]Anti-inflammatory1670.50 (*p* value 0.003)1 SD changeDay 1 Peptidase inhibitor 3Wang 2017 \[[@CR105]\]Anti-inflammatory1670.43 (*p* value 0.001)1 SD changeDay 3 Peptidase inhibitor 3Wang 2017 \[[@CR105]\]Anti-inflammatory1670.70 (*p* value 0.18)1 SD changeDay 7 Plasminogen activator inhibitor 1Cartin-Ceba 2015 \[[@CR67]\]Coagulation1000.96 (0.62--1.47)Per log10 Plasminogen activator inhibitor 1 (activity)Tsangaris 2009 \[[@CR101]\]Coagulation521.30 (0.84--1.99)Per 1 unit increase ProcalcitoninAdamzik 2013 \[[@CR58]\]Inflammation471.01 (0.025--1.2)Per log10 ProcalcitoninRahmel 2018 \[[@CR94]\]Inflammation1190.999 (0.998--1.001) Protein CMcClintock 2008 \[[@CR86]\]Coagulation500.5 (0.2--1.0)Per natural log Protein CTsangaris 2017 \[[@CR102]\]Coagulation533.58 (0.73--15.54)\< 41.5 mg/dL Receptor for advanced glycation end productsCalfee 2008 \[[@CR62]\]Alveolar epithelial injury6761.41 (1.12--1.78)Per log10Tidal volume 12 mL/kg Receptor for advanced glycation end productsCalfee 2008 \[[@CR62]\]Alveolar epithelial injury6761.03 (0.81--1.31)Per log10Tidal volume 6 mL/kg Receptor for advanced glycation end productsCalfee 2015 \[[@CR66]\]Alveolar epithelial injury1001.98 (1.18--3.33)Per log10Single centre Receptor for advanced glycation end productsCalfee 2015 \[[@CR66]\]Alveolar epithelial injury8531.16 (1.003--1.34)Per log10Multicentre Receptor for advanced glycation end productsCartin-Ceba 2015 \[[@CR67]\]Alveolar epithelial injury1000.81 (0.50--1.30)Per log10 Receptor for advanced glycation end productsMrozek 2016 \[[@CR89]\]Alveolar epithelial injury1193.1 (1.1--8.9)-- Soluble suppression of tumourigenicity-2Bajwa 2013 \[[@CR61]\]Myocardial strain and inflammation8261.47 (0.99--2.20)≥ 534 ng/mL (day 0)Day 0 Soluble suppression of tumourigenicity-2Bajwa 2013 \[[@CR61]\]Myocardial strain and inflammation8262.94 (2.00--4.33)≥ 296 ng/mL (day 3)Day 3 Soluble triggering receptor expressed on myeloid cells-1Lin 2010 \[[@CR80]\]Pro-inflammatory636.338 (1.607--24.998)Per log 10 Surfactant protein-AEisner 2003 \[[@CR72]\]Alveolar epithelial injury5650.92 (0.68--1.27)Per 100 ng/mL increment Surfactant protein DCalfee 2011 \[[@CR64]\]Alveolar epithelial injury5471.55 (1.27--1.88)Per natural log Surfactant protein DCalfee 2015 \[[@CR66]\]Alveolar epithelial injury1001.33 (0.82--2.14)Per log10Single centre Surfactant protein DCalfee 2015 \[[@CR66]\]Alveolar epithelial injury8531.09 (0.95--1.24)Per log10Multicentre Surfactant protein DEisner 2003 \[[@CR72]\]Alveolar epithelial injury5651.21 (1.08--1.35)Per 100 ng/mL increment Thrombin--antithrombin III complexCartin-Ceba 2015 \[[@CR67]\]Coagulation1001.05 (0.53--2.05)Per log10 High sensitivity troponin IMetkus 2017 \[[@CR88]\]Myocardial injury10570.94 (0.64--1.39)1st, 5th quintile Cardiac troponin TRivara 2012 \[[@CR96]\]Myocardial injury1771.44 (1.14--1.81)Per 1 ng/mL increase TrombomodulinSapru 2015 \[[@CR98]\]Coagulation4492.40 (1.52--3.83)Per log10Day 0 TrombomodulinSapru 2015 \[[@CR98]\]Coagulation4492.80 (1.69--4.66)Per log10Day 3 Tumour necrosis factor alphaLin 2010 \[[@CR80]\]Pro-inflammatory633.691 (0.668--20.998)Per log 10 Tumour necrosis factor receptor-1Calfee 2011 \[[@CR64]\]Pro-inflammatory5471.58 (1.20--2.09)Per natural log Tumour necrosis factor receptor-1Parsons 2005 \[[@CR91]\]Pro-inflammatory5625.76 (2.63--12.6)Per log10 Tumour necrosis factor receptor-2Parsons 2005 \[[@CR91]\]Pro-inflammatory3762.58 (1.05--6.31)Per log10 Uric acidLee 2019 \[[@CR77]\]Antioxidant2370.549 (0.293--1030)≥ 3.00 mg/dL Von Willebrand factorCalfee 2011 \[[@CR64]\]Endothelial activation, coagulation5471.57 (1.16--2.12)Per natural log Von Willebrand factorCalfee 2012 \[[@CR65]\]Endothelial activation, coagulation9311.51 (1.20--1.90)Per log10 Von Willebrand factorCalfee 2015 \[[@CR66]\]Endothelial activation, coagulation8531.83 (1.46--2.30)Per log10Multicentre Von Willebrand factorCartin-Ceba 2015 \[[@CR67]\]Endothelial activation, coagulation1002.93 (0.90--10.7)Per log10 Von Willebrand factorWare 2004 \[[@CR107]\]Endothelial activation, coagulation5591.6 (1.4--2.1)Per SD increment**Biomarkers in BALF** Angiopoietin-2Tsangaris 2017 \[[@CR102]\]Increased endothelial permeability5311.18 (1.06--117.48)\> 705 pg/mL Fibrocyte percentageQuesnel 2012 \[[@CR93]\]Pro-fibrotic926.15 (2.78--13.64)\> 6% Plasminogen activator inhibitor 1 (activity)Tsangaris 2009 \[[@CR101]\]Coagulation520.37 (0.06--2.35)Per 1 unit increase Procollagen IIIClark 1995 \[[@CR69]\]Pro-fibrotic1173.6 (1.2--10.7)≥ 1.75 U/mL Procollagen IIIForel 2015 \[[@CR73]\]Pro-fibrotic515.02 (2.06--12.25)≥ 9 μg/L Transforming growth factor alphaMadtes 1998 \[[@CR83]\]Pro-fibrotic742.3 (0.7--7.0)\> 1.08 pg/mL Transforming growth factor beta 1Forel 2018 \[[@CR74]\]Pro-fibrotic621003 (0.986--1.019) T regulatory cell/CD4+ lymphocyte ratioAdamzik 2013 \[[@CR58]\]Immunomodulation476.5 (1.7--25)≥ 7.4%**Biomarkers in urine** Desmosine-to-creatinine ratioMcClintock 2006 \[[@CR84]\]Alveolar epithelial injury (elastin breakdown)5791.36 (1.02--1.82)Per log10 Nitric oxideMcClintock 2007 \[[@CR85]\]Oxidative injury5760.33 (0.20--0.54)Per log10 Nitric oxide-to-creatinine ratioMcClintock 2007 \[[@CR85]\]Oxidative injury5760.43 (0.28--0.66)Per log10*Abbreviations*: *ALI* acute lung injury, *BALF* bronchoalveolar lavage fluid, *SD* standard deviation

Discussion {#Sec12}
==========

In the current systematic review, we present a synopsis of biomarkers for ARDS development and mortality tested in multivariate analyses. We did not perform a meta-analysis because of severe data heterogeneity between studies. Upon qualitative inspection, we found that high levels of Ang-2 and RAGE were associated with ARDS development in the at-risk population. None of the biomarkers assessed in four or more studies was associated with an increased mortality rate in all studies. The majority of plasma biomarkers for both ARDS development and mortality are surrogates for inflammation in ARDS pathophysiology.

Previously, Terpstra et al. \[[@CR19]\] calculated univariate ORs from absolute biomarker concentrations and performed a meta-analysis. They found that 12 biomarkers in plasma were associated with mortality in patients with ARDS. However, a major limitation of their meta-analysis is that these biomarkers were tested in univariate analyses without considering confounders as disease severity scores. Given the high univariate ORs as compared to the multivariate ORs found in this systematic review, the performance of these biomarkers is likely to be overestimated. Jabaudon et al. \[[@CR109]\] found in an individual patient data meta-analysis that high concentrations of plasma RAGE were associated with 90-day mortality independent of driving pressure or tidal volume. However, they could not correct for disease severity score as these differed between studies. Unfortunately, we were unable to perform a meta-analysis on multivariate data because of heterogeneity of the included studies, as transformation of raw data, biomarker concentration cut-offs, time until outcome, and the variables used in the multivariate analyses varied widely between studies. This could be an incentive to standardize the presentation of ARDS biomarker research in terms of statistics and outcome for future analyses or to make individual patient data accessible.

ARDS biomarkers are presumed to reflect the pathophysiology of ARDS, characterized by alveolar-capillary membrane injury, high permeability alveolar oedema, and migration of inflammatory cells \[[@CR3]\]. Previously, Terpstra et al. \[[@CR19]\] proposed that biomarkers for ARDS development were correlated with alveolar tissue injury, whereas biomarkers for ARDS mortality correlated more with inflammation. In this systematic review, we found that the majority of biomarkers tested for both ARDS development and mortality were surrogates for inflammation. However, following qualitative inspection, biomarkers for inflammation were not evidently associated with either ARDS development or mortality. In contrast, markers for alveolar epithelial injury (plasma RAGE and SpD) and endothelial permeability (plasma Ang-2) seem to be associated with ARDS development. Therefore, we should consider how we intend to use (a set of) biomarkers in patients with ARDS.

A biomarker for ARDS development should be specific for ARDS, i.e. a biomarker that reflects alveolar injury or alveolar-capillary injury. Half of plasma biomarkers for ARDS development included in this study reflected inflammation. An increase in inflammatory biomarkers is known to correlate with increased disease severity scores \[[@CR71], [@CR97], [@CR110]\]. In turn, the majority of studies in this review found significantly higher disease severity scores in the critically ill patients that eventually developed ARDS. Thus, plasma biomarkers for inflammation rather represented an estimation of disease severity and its associated increased risk for the development of ARDS. In addition, biomarkers for inflammation in plasma lack the specificity to diagnose ARDS, as they are unlikely to differentiate sepsis with ARDS from sepsis without ARDS. In contrast, locally sampled biomarkers for inflammation, for example in the alveolar space, could potentially diagnose ARDS \[[@CR111]\]. Biomarkers used for ARDS mortality or for the identification of less heterogeneous ARDS phenotypes do not require to be ARDS specific, provided that they adequately predict or stratify patients with ARDS.

The heterogeneity of ARDS has been recognized as a major contributor to the negative randomized controlled trial results among patients with ARDS \[[@CR11]\]. Therefore, it is necessary to identify homogeneous ARDS phenotypes that are more likely to respond to an intervention. This is known as predictive enrichment \[[@CR112]\]. Previously, patients with ARDS have been successfully stratified based on clinical parameters, such as ARDS risk factor (pulmonary or extra-pulmonary) or PaO~2~/FiO~2~ ratio \[[@CR113]\]. ARDS biomarkers could be used to stratify patients with ARDS based on biological or pathophysiological phenotype. For example, trials of novel therapies designed to influence vascular permeability may benefit from preferentially enrolling patients with high Ang-2 concentrations. Recently, clinical parameters have been combined with a set of biomarkers in a retrospective latent class analysis. In three trials, two distinct phenotypes were found: hyperinflammatory and hypoinflammatory ARDS \[[@CR16], [@CR17]\]. Patients with the hyperinflammatory phenotype had reduced mortality rate with higher positive end-expiratory pressures and with liberal fluid treatment, whereas the trials themselves found no difference between the entire intervention groups. The next step is to validate the identification of ARDS phenotypes based on latent class analysis in prospective studies. An adequate combination of biomarkers and clinical parameters remains to be established. Until now, there is no list of biomarkers that are associated with ARDS development or mortality independently of clinical parameters. This systematic review may guide the selection of ARDS biomarkers used for predictive enrichment.

This systematic review has limitations. First, the intent of this systematic review was to perform a meta-analysis. However, we decided not to perform a meta-analysis, as the biomarker data handling and outcomes varied widely among studies, and pooling would have resulted in a non-informative estimate \[[@CR21]\]. Arguably, this is a positive result, as it refrains us from focusing on the few biomarkers that could be pooled in a meta-analysis and guides us into a direction were multiple biomarkers combined with other parameters are of interest. In a heterogeneous syndrome as ARDS, the one biomarker probably does not exist. Second, the first sampling moment varied between sampling at ICU admission until 72 h following ICU admission. Initially, ARDS is characterized by an exudative phase followed by a second proliferative phase and late fibrotic phase \[[@CR3]\]. The moment of sampling likely influences biomarker concentrations, as both alveolar membrane injury and inflammation increase during the exudative phase. This is also seen in six biomarkers that have been measured at separate days, resulting in a significant change in adjusted OR for four biomarkers (Table [4](#Tab4){ref-type="table"}) \[[@CR61], [@CR98], [@CR104], [@CR105]\]. Third, the aim of this systematic review was to assess the independent risk effects of biomarkers measured in various bodily fluid compartments. However, the majority of studies assessed biomarkers in plasma. It remains to be answered whether other bodily fluid compartments, for example from the airways and alveolar space themselves, might outperform ARDS biomarkers in plasma, especially for ARDS development. Fourth, all studies found in this systematic review used a clinical definition of ARDS as standard for ARDS diagnosis. Given the poor correlation between a clinical diagnosis and a histopathological diagnosis of ARDS, these studies are diagnosing a very heterogeneous disease syndrome \[[@CR7]--[@CR10]\]. In order to actually evaluate ARDS development, biomarkers should be compared to a histopathological image of DAD, although acquiring histology poses great challenges by itself. Fifth, as only biomarkers assessed in multivariate analyses were included in this study, new promising biomarkers evaluated in univariate analyses were excluded from this study. Lastly, non-significant biomarkers in multivariate analyses were more likely not to be reported, although some studies report non-significant results nonetheless.

Conclusion {#Sec13}
==========

In here, we present a list of biomarkers for ARDS mortality and ARDS development tested in multivariate analyses. In multiple studies that assessed Ang-2 and RAGE, high plasma levels were associated with an increased risk of ARDS development. We did not find a biomarker that independently predicted mortality in all studies that assessed the biomarker. Furthermore, biomarker data reporting and variables used in multivariate analyses differed greatly between studies. Taken together, we should look for a combination of biomarkers and clinical parameters in a structured approach in order to find more homogeneous ARDS phenotypes. This systematic review may guide the selection of ARDS biomarkers for ARDS phenotyping.
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AECC

:   American European Consensus Conference

Ang-2

:   Angiopoeitin-2

ARDS

:   Acute respiratory distress syndrome

CRP

:   C-reactive protein

DAD

:   Diffuse alveolar damage

IL-8

:   Interleukin-8

NOS

:   Newcastle-Ottawa Scale

OR

:   Odds ratio

RAGE

:   Receptor for advanced glycation end products

SpD

:   Surfactant protein D

VWF

:   Von Willebrand factor
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